Drug Prices
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023. These increases led to $815 million incremental added costs for U.S. payers.
The AHA supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs for a low, fixed copayment no higher than $2 for a month’s supply per drug.
AHA comments regarding the Centers for Medicare & Medicaid Services Medicare $2 Drug List (M2DL) Model request for information (RFI).
The Centers for Medicare & Medicaid Services (CMS) Oct. 2 released its final guidance on implementing the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program.
The Centers for Medicare & Medicaid Services Oct. 9 released a request for information and a sample list of prescription drugs it intends to include under a proposed Medicare $2 Drug List Model.
The Department of Health and Human Services Oct. 2 released final guidance detailing the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program.
The Centers for Medicare & Medicaid Services Sept. 27 announced that average premiums, benefits and plan choices for Medicare Advantage and Part D will remain stable for 2025.
The Centers for Medicare & Medicaid Aug. 15 announced it negotiated lower prices with drug makers for 10 high-cost, sole-source drugs, with the new prices becoming effective in 2026 for individuals with Medicare Part D coverage.
Our shared focus with Congress and Administration is on providing relief from the pandemic, ensuring a smooth recovery, and rebuilding a better health care system for the future. The ºÚÁÏÕýÄÜÁ¿ Association continues to incorporate principles that promote improved affordability, value, and…
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year.